Tags : Report

Clinical Trials

Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER

Shots: The P-III COV-BARRIER study involves assessing Baricitinib (4mg, qd) + SoC (which included 79% receiving corticosteroids and 19% receiving remdesivir, with some receiving both) vs PBO + SoC in 1525 patients in a ratio (1:1) hospitalized with COVID-19 The trial did not meet 1EPs i.e. progression to non-invasive ventilation or invasive mechanical ventilation including […]Read More